KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EPS (Weighted Average and Diluted) (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed EPS (Weighted Average and Diluted) for 12 consecutive years, with -$0.01 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 85.71% to -$0.01 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.17 through Dec 2025, up 55.26% year-over-year, with the annual reading at -$0.17 for FY2025, 55.26% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.01 in Q4 2025 for Arbutus Biopharma, up from -$0.04 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.01 in Q2 2025 to a low of -$0.24 in Q3 2021.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.11 across 5 years, with a median of -$0.11 in 2022.
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 109.09% in 2025; the steepest drop was 30.0% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.15 in 2021, then grew by 6.67% to -$0.14 in 2022, then increased by 14.29% to -$0.12 in 2023, then soared by 41.67% to -$0.07 in 2024, then soared by 85.71% to -$0.01 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ABUS at -$0.01 in Q4 2025, -$0.04 in Q3 2025, and $0.01 in Q2 2025.